號: 保存年限:

新北市政府衛生局 函

地址: 22006新北市板橋區英士路192-1號

承辦人:王峙懿

電話: (02)22577155 分機1307

傳真:(02)22536548

電子信箱: AP6125@ntpc. gov. tw

24158

新北市三重區重新路5段646號8樓

受文者:新北市藥師公會

發文日期:中華民國104年11月30日 發文字號:新北衛食字第1042281385號

速別:普通件

密等及解密條件或保密期限: 附件:仿冒藥品訊息相關資料1份

主旨:有關「Postinor-2」藥品之仿冒品於東非地區流通,為維護 國民之健康與安全,請轉知所屬會員勿販售供應與使用,請 杳昭。

說明:

一、依據衛生福利部食品藥物管理署104年11月25日FDA企字第 1041205162號函辦理。

二、檢附仿冒藥品訊息相關資料1份。

正本:新北市藥師公會、新北市藥劑生公會、新北市醫師公會、新北市西藥商業同

業公會、新北市商業會 副本:新北市政府衛生局衛生稽查科



本案依分層負責規定授權業務主管決行



20. AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Ref. RHT/SAV/Alert 5.2015

18 November 2015

Medical Product Alert No 5/2015

Falsified Emergency Contraceptive circulating in East Africa

This Medical Product Alert relates to the confirmed circulation of falsified versions of Postinor-2 (Levonorgestrel) in East Africa.

Postinor-2 is a widely used emergency contraceptive that should contain 0.75mg of levonorgestrel. The genuine product is manufactured by Gedeon Richter.

In August 2015, the Uganda National Drug Authority notified WHO of the seizure of falsified Postinor-2 discovered in Kampala, Uganda. All packs reported bear the same batch number and expiry/manufacturing dates.

The details of the product are as follows:

Product Name:

Postinor-2

Batch Number:

T38012

Manufacturing Date:

08 2013

Expiry Date:

08 2018

There is a non-useable white "scratch area" on the reverse side of the pack, (see photograph below). The packaging is in English, French and Spanish languages.

The batch number and manufacturing/expiry dates relate to a genuine batch of Postinor-2. <u>Laboratory analysis has shown that the product contains zero active pharmaceutical ingredient</u>. Furthermore, the manufacturers of genuine Postinor-2 have confirmed the packaging is falsified.


If you are in possession of the same batch of Postinor-2 shown in the below photograph and with a non-useable white "scratch area" on the reverse side of the pack please do not use, contact a Pharmacist or a Doctor as soon as possible for advice and report the incident to your National Medicines Regulatory Authority.

If you think you have taken this product, please seek medical advice immediately.

If you have any information concerning the supply of this product please contact rapidalert@who.int



20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT



WHO Surveillance and Monitoring – Rapid Alert Substandard, Spurious, Falsely labelled, Falsified and Counterfeit (SSFFC) Medical Products

All WHO Drug Alerts are available at the following link: http://www.who.int/medicines/publications/drugalerts/en/